A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma

Abstract

ABSTRACT Epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) is an important subtype of lung cancer. With the existing and ongoing research and multiple targeted therapeutic options available, the treatment landscape of this subset is rapidly evolving. This is the first review article in the series on EGFR-mutant NSCLC in which we describe the structure of EGFR, the molecular biology of common EGFR mutations, diagnostic modalities, and various treatment options for all stages of NSCLC harboring common EGFR mutations. We searched for the articles in various databases including OncoKB, NCBI: PubMed, Embase, Scopus, and MyCancerGenome, using the keywords “EGFR”, “NSCLC”, “Osimertinib”, and “Gefitinib”. To compile this review, a total of 132 articles were utilized.